MoonLake Immunotherapeutics Reports Robust Phase 3 Outcomes for Sonelokimab in Hidradenitis Suppurativa
MoonLake Immunotherapeutics (NASDAQ: MLTX) announced the Week 40 results from its Phase 3 VELA‑1 and VELA‑2 trials, showing that the investigational nanobody Sonelokimab (SLK) continues to deliver clinically meaningful benefits in patients with moderate‑to‑severe hidradenitis suppurativa (HS). The data were disclosed on March 28, 2026 and will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
Key Findings
| Metric | Result | Context |
|---|---|---|
| Primary endpoint – HiSCR 75 at Week 16 | 62 % of patients achieved a ≥ 75 % reduction in abscess and inflammatory nodule count with no worsening of abscess or draining tunnels | Demonstrates a significant and durable clinical response in a disease with limited treatment options |
| Week 40 sustained response | 62 % of patients remained above HiSCR 75 | Indicates that the benefit persists well beyond the primary endpoint |
| Secondary endpoints | Improvements in HS Quality of Life score and other patient‑reported outcomes | Supports the clinical relevance of Sonelokimab beyond lesion counts |
The VELA program enrolled 838 adults globally in a double‑blind, placebo‑controlled design. Sonelokimab targets both IL‑17A and IL‑17F, offering a broader mechanism of action than many existing biologics.
Analyst Commentary
- Cantor Fitzgerald reiterated its “Buy” rating on the basis of favorable regulatory prospects, noting that the sustained efficacy data strengthen the case for a potential FDA filing.
- BTIG also reaffirmed its “Buy” stance, citing the strong Week 40 results and the company’s pipeline focus on HS.
- Investing.com and de.investing.com published matching reports that confirm Cantor Fitzgerald’s assessment, emphasizing the regulatory outlook.
These endorsements come as the company’s share price has experienced modest upward momentum in a sector‑wide rally, with peers such as SLNO, SRRK, MLTX, and RARE all moving higher.
Market Snapshot
- Current Price (2026‑03‑30): $18.64
- 52‑Week High (2025‑09‑25): $62.75
- 52‑Week Low (2025‑09‑28): $5.95
- Market Capitalization: $1.21 billion
- Price‑to‑Earnings Ratio: –4.71 (reflecting the company’s clinical‑stage status)
The company’s clinical achievements have outpaced its recent valuation, underscoring the potential upside if regulatory approval materializes.
Strategic Implications
MoonLake’s focus on Sonelokimab, a nanobody platform, aligns with its broader strategy to unlock novel therapeutic modalities for inflammatory diseases. The robust Phase 3 data position the company as a compelling candidate for FDA submission, potentially accelerating its path to commercial launch. Continued monitoring of regulatory milestones and forthcoming presentations at the AAD conference will be pivotal for investors and patients alike.
All figures and statements are drawn exclusively from the provided fundamentals and news excerpts. No additional external sources were consulted.
